Enterprise Value

1.696B

Cash

791.3M

Avg Qtr Burn

-101.4M

Short % of Float

14.42%

Insider Ownership

1.21%

Institutional Own.

93.43%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NTLA-2001 (CRISPR/Cas9) Details
Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy, Cardiomyopathy

Phase 3

Update

NTLA-2001 (CRISPR/Cas9) Details
Hereditary transthyretin amyloidosis, Polyneuropathy

Phase 3

Initiation

NTLA-2002 (KLKB1 Inhibitor) Details
Hereditary angioedema , Rare diseases, Rare genetic disease

Phase 1/2

Data readout

NTLA-3001 Details
Alpha-1 Antitrypsin Deficiency, Lung disease

Phase 1

Initiation

NTLA-5001 Details
Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued